Effect of Intravenous Immunglobulin (IVIG) After Myocardial Infarction
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The instigators hypothesize that IVIG, given in the acute phase following MI in patients at
risk for developing HF, will improve cardiac performance, and by attenuating cardiac
remodeling in this phase, such therapy will prevent the development of chronic HF resulting
in long term beneficial effect also after the therapy has been stopped.